Accelerate Diagnostics to Participate Virtually in 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022

Rhea-AI Summary

Accelerate Diagnostics, Inc. (Nasdaq: AXDX) will present at the 40th Annual J. P. Morgan Healthcare Conference on January 13, 2022, at 9:45 a.m. Eastern Time. A live webcast of the presentation will be available online. The company specializes in in vitro diagnostics, focusing on antibiotic resistance and sepsis. Its Accelerate Pheno® system reports antibiotic susceptibility results in about 7 hours, significantly faster than traditional methods. This advancement supports clinicians in optimizing patient-specific antibiotic therapy.

TUCSON, Ariz., Dec. 29, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) announced today that the company is scheduled to present at the 40^th Annual J. P. Morgan Healthcare Conference on January 13, 2022, at 9:45a.m. Eastern.

A live webcast of the presentation will be accessible through the public direct webcast link: 

https://jpmorgan.metameetings.net/events/healthcare22/sessions/40546-accelerate-diagnostics-inc/webcast?gpu_only=true&kiosk=true

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno^® system and Accelerate PhenoTest^® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as, among others, our estimates of the fourth quarter and further 2020 financial results, our expectation of closing our contracted $32.0 million in private financing, and Mr. Phillips' statement that in 2021 we expect further sales and implementation optimization, improving COVID-19 pandemic conditions, and new product launches will accelerate our rate of new customer adoption. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 27, 2020, and in any other reports that the company files with the Securities and Exchange Commission. The company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.

View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-to-participate-virtually-in-40th-annual-j-p-morgan-healthcare-conference-on-january-13-2022-301451264.html

SOURCE Accelerate Diagnostics, Inc.

FAQ

When is Accelerate Diagnostics presenting at the J. P. Morgan Healthcare Conference?

Accelerate Diagnostics is scheduled to present on January 13, 2022, at 9:45 a.m. Eastern Time.

How can I access the webcast for Accelerate Diagnostics' presentation?

The live webcast can be accessed through the provided link: https://jpmorgan.metameetings.net/events/healthcare22/sessions/40546-accelerate-diagnostics-inc/webcast?gpu_only=true&kiosk=true.

What does Accelerate Diagnostics specialize in?

Accelerate Diagnostics focuses on in vitro diagnostics, particularly solutions for antibiotic resistance and sepsis.

What is the significance of the Accelerate Pheno® system?

The Accelerate Pheno® system reports antibiotic susceptibility results in approximately 7 hours, enabling faster, more accurate patient care.

What is the stock symbol for Accelerate Diagnostics?

The stock symbol for Accelerate Diagnostics is AXDX.